Haemonetics Earnings Call Transcripts
Fiscal Year 2026
-
Management highlighted strong execution on a four-year transformation plan, surpassing growth and earnings targets, and set conservative FY 2027 guidance of 3%-6% organic growth. Key drivers include innovation, share gains, and operational leverage, with upside potential from faster technology adoption and market stabilization.
-
Management highlighted robust revenue and margin growth, driven by core products and innovation in plasma and hospital businesses. Vascular closure is rebounding, and blood management technologies are accelerating. The company is focused on organic growth, margin expansion, and capital returns.
-
Q4 and full-year results showed strong organic growth, margin expansion, and robust free cash flow, driven by Plasma and TEG platforms. Fiscal 2027 guidance projects continued revenue and margin growth, with innovation and portfolio transformation supporting future performance.
-
The conference highlighted record plasma business growth, successful innovation cycles, and robust financial performance, with strong share gains and new product launches like Persona PLUS and PerQseal Elite. The company is focused on sustainable growth, operational improvements, and disciplined capital deployment.
-
Strong Q3 results led to raised full-year guidance for revenue, earnings, and cash flow. Plasma and blood management technologies drove growth, while interventional technologies faced headwinds but are expected to recover in FY27. Margin expansion and robust cash flow support ongoing investments.
-
The conference highlighted strong financial performance, with high-margin growth driven by three core platforms: plasma, TEG, and vascular closure. Recent acquisitions and innovation pipelines are set to expand market leadership, while disciplined capital allocation supports future growth.
-
Second quarter results showed strong organic growth in core products, record margin expansion, and robust cash flow, leading to raised full-year guidance for revenue, EPS, and free cash flow. Plasma and blood management technologies outperformed, while targeted actions are underway to restore growth in interventional technologies.
-
Q1 saw 13% organic revenue growth ex-CSL, 8% adjusted EPS growth, and margin expansion, despite a 4% reported revenue decline from portfolio transitions. Guidance for the year is reaffirmed, with strong performance in Plasma and Hospital segments, and ongoing executional improvements in Interventional Technologies.
Fiscal Year 2025
-
The company has transformed its portfolio, shifting focus from plasma to high-growth hospital and interventional technologies, achieving double-digit revenue and earnings growth. With reduced customer concentration risk and robust margin expansion, it plans to issue a new three-year LRP targeting continued above-market growth and disciplined M&A.
-
Delivered strong FY2025 results with margin expansion, robust cash flow, and double-digit growth in hospital and interventional technologies. FY2026 guidance anticipates continued margin gains, organic growth, and significant share gains in plasma, despite headwinds from divestitures and CSL transition.
-
The business has shifted to focus on high-growth, high-margin core products, with plasma and interventional technologies driving performance. Plasma growth is supported by technology upgrades and share gains, while hospital and blood management segments show strong momentum. Margin expansion and cash flow improvement are expected, with a conservative outlook for FY26.
-
Third quarter results showed 4% reported revenue growth and 14% higher adjusted EPS, with record margins driven by strong hospital performance and portfolio transformation. Guidance was updated for modest revenue growth, continued margin expansion, and robust cash flow, despite plasma and China headwinds.
-
Record financial performance and margin expansion are being driven by a strategic shift to high-growth, high-margin products, with plasma and hospital businesses as key engines. Ongoing innovation, M&A, and operational excellence support robust growth and future value creation.
-
Second quarter revenue grew 9% reported and 4% organically, with hospital segment driving strong growth and plasma segment impacted by customer transitions. Adjusted EPS rose 13% year-over-year, margins expanded, and guidance was raised for organic growth in both total and hospital revenues.
-
Revenue grew 8% reported and 3% organically, with strong hospital and interventional performance offsetting plasma and blood center declines. Margin expansion was driven by acquisitions and new products, while guidance for FY25 was reaffirmed across all key metrics.